SIGA Technologies, Inc. - Product Pipeline Review - 2015

SIGA Technologies, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report provides an overview of the SIGA Technologies, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SIGA Technologies, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ SIGA Technologies, Inc. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of SIGA Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of SIGA Technologies, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the SIGA Technologies, Inc.’s pipeline products

Reasons to buy

- Evaluate SIGA Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of SIGA Technologies, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the SIGA Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of SIGA Technologies, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SIGA Technologies, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of SIGA Technologies, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Aptose Biosciences Inc. - Product Pipeline Review - 2015

Aptose Biosciences Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report provides an overview of the Aptose Biosciences Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aptose Biosciences Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Aptose Biosciences Inc. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Aptose Biosciences Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Aptose Biosciences Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Aptose Biosciences Inc.’s pipeline products

Reasons to buy

- Evaluate Aptose Biosciences Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Aptose Biosciences Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Aptose Biosciences Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Aptose Biosciences Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aptose Biosciences Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Aptose Biosciences Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues 

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report  provides an overview of the Vitae Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vitae Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Vitae Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vitae Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Vitae Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Vitae Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vitae Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vitae Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vitae Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vitae Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vitae Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Glucox Biotech AB - Product Pipeline Review - 2015

Glucox Biotech AB - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report  provides an overview of the Glucox Biotech AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Glucox Biotech AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Glucox Biotech AB - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Glucox Biotech AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Glucox Biotech AB’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Glucox Biotech AB’s pipeline products

Reasons to buy

- Evaluate Glucox Biotech AB’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Glucox Biotech AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Glucox Biotech AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Glucox Biotech AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Glucox Biotech AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Glucox Biotech AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hawaii Biotech, Inc. - Product Pipeline Review - 2015

Hawaii Biotech, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report provides an overview of the Hawaii Biotech, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hawaii Biotech, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Hawaii Biotech, Inc. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Hawaii Biotech, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Hawaii Biotech, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Hawaii Biotech, Inc.’s pipeline products

Reasons to buy

- Evaluate Hawaii Biotech, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Hawaii Biotech, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Hawaii Biotech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Hawaii Biotech, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hawaii Biotech, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Hawaii Biotech, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

WhanIn Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

WhanIn Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report provides an overview of the WhanIn Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of WhanIn Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ WhanIn Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of WhanIn Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of WhanIn Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the WhanIn Pharmaceutical Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate WhanIn Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of WhanIn Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the WhanIn Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of WhanIn Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of WhanIn Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of WhanIn Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Flexion Therapeutics, Inc. - Product Pipeline Review - 2015

Flexion Therapeutics, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report provides an overview of the Flexion Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Flexion Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Flexion Therapeutics, Inc. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Flexion Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Flexion Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Flexion Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Flexion Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Flexion Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Flexion Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Flexion Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Flexion Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Flexion Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

LFB S.A. - Product Pipeline Review - 2015

LFB S.A. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report provides an overview of the LFB S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of LFB S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ LFB S.A. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of LFB S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of LFB S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the LFB S.A.’s pipeline products

Reasons to buy

- Evaluate LFB S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of LFB S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the LFB S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of LFB S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of LFB S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of LFB S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

CHA Bio & Diostech Co., Ltd. - Product Pipeline Review - 2015

CHA Bio & Diostech Co., Ltd. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.This report  provides an overview of the CHA Bio & Diostech Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CHA Bio & Diostech Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ CHA Bio & Diostech Co., Ltd. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of CHA Bio & Diostech Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CHA Bio & Diostech Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CHA Bio & Diostech Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate CHA Bio & Diostech Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CHA Bio & Diostech Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CHA Bio & Diostech Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CHA Bio & Diostech Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CHA Bio & Diostech Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CHA Bio & Diostech Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Kaketsuken K.K. - Product Pipeline Review - 2015

Kaketsuken K.K.-Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Kaketsuken K.K.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kaketsuken K.K.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Kaketsuken K.K. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Kaketsuken K.K. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kaketsuken K.K.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Kaketsuken K.K.’s pipeline products

Reasons to buy

- Evaluate Kaketsuken K.K.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kaketsuken K.K. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kaketsuken K.K.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kaketsuken K.K. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kaketsuken K.K.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kaketsuken K.K. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

HAL Allergy BV - Product Pipeline Review - 2015

HAL Allergy BV - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the HAL Allergy BV’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of HAL Allergy BV’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ HAL Allergy BV - Product Pipeline Review - 2015

Scope

- The report provides brief overview of HAL Allergy BV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of HAL Allergy BV’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the HAL Allergy BV’s pipeline products

Reasons to buy

- Evaluate HAL Allergy BV’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of HAL Allergy BV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the HAL Allergy BV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of HAL Allergy BV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of HAL Allergy BV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of HAL Allergy BV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Laboratorios SALVAT S.A. - Product Pipeline Review - 2015

Laboratorios SALVAT S.A. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report  provides an overview of the Laboratorios SALVAT S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Laboratorios SALVAT S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Laboratorios SALVAT S.A. - Product Pipeline Review - 2015

Scope

- The report provides brief overview of Laboratorios SALVAT S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Laboratorios SALVAT S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Laboratorios SALVAT S.A.’s pipeline products

Reasons to buy

- Evaluate Laboratorios SALVAT S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Laboratorios SALVAT S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Laboratorios SALVAT S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Laboratorios SALVAT S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Laboratorios SALVAT S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Laboratorios SALVAT S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

GlycaNova Norway AS - Product Pipeline Review - 2015

GlycaNova Norway AS - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack.

This report provides an overview of the GlycaNova Norway AS’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of GlycaNova Norway AS’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ GlycaNova Norway AS - Product Pipeline Review - 2015

Scope

- The report provides brief overview of GlycaNova Norway AS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GlycaNova Norway AS’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GlycaNova Norway AS’s pipeline products

Reasons to buy

- Evaluate GlycaNova Norway AS’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GlycaNova Norway AS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GlycaNova Norway AS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GlycaNova Norway AS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlycaNova Norway AS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GlycaNova Norway AS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Spinal Cord Stimulators - Pipeline Review, 2015

Spinal Cord Stimulators - Pipeline Review, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Spinal Cord Stimulators currently in pipeline stage.The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Spinal Cord Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Complete report available @ Spinal Cord Stimulators - Pipeline Review, 2015

Scope

- Extensive coverage of the Spinal Cord Stimulators under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Spinal Cord Stimulators and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Spinal Cord Stimulators under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date


Companies Mentioned

Boston Scientific Corporation Direct Spinal Therapeutics, Inc. Duke University Imperial College London Meagan Medical Inc. Medtrode Inc. Medtronic plc MicroTransponder Inc. NeuroRecovery Technologies Inc. Nuvectra Corporation Saluda Medical Pty Ltd St. Jude Medical, Inc. Stimwave Technologies, Inc.



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Vagus Nerve Stimulators - Pipeline Review, 2015

Vagus Nerve Stimulators - Pipeline Review, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Vagus Nerve Stimulators currently in pipeline stage.The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Complete report available @ Vagus Nerve Stimulators - Pipeline Review, 2015

Scope

- Extensive coverage of the Vagus Nerve Stimulators under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Vagus Nerve Stimulators under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date


Companies Mentioned

BioControl Medical Boston Scientific Corporation CerboMed GmbH Cerebral RX Ltd. Children's Hospital Boston Cyberonics, Inc. DuoCure Ltd. ElectroCore, LLC Medical University of South Carolina MicroTransponder Inc. Neurostream Technologies G.P. Setpoint Medical Corporation Sorin S.p.A. Trifectas Medical Corp.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Refractive Surgery Devices - Pipeline Review, 2015

Refractive Surgery Devices - Pipeline Review, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Refractive Surgery Devices currently in pipeline stage.The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Refractive Surgery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Complete report available @ Refractive Surgery Devices - Pipeline Review, 2015

Scope

- Extensive coverage of the Refractive Surgery Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Refractive Surgery Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Refractive Surgery Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date


Companies Mentioned

Alcon, Inc. Avedro, Inc. Belkin Laser Ltd Biolase, Inc. Carl Zeiss Meditec AG CV Laser Pty Ltd IFS Construction Services Ltd Lensar, Inc. Massachusetts Eye and Ear Infirmary Nidek Co., Ltd. Oraya Therapeutics, Inc. Princeton University Rowiak GmbH Spire Corporation STAAR Surgical Company Stroma Medical Corp Technolas Perfect Vision GmbH (Inactive) University of Bern University of Calgary Visioneering Technologies, Inc. Wake Forest Baptist Medical Center



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Goiter Global Clinical Trials Review, H2, 2015

Goiter Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Goiter clinical trials scenario. This report provides top line data relating to the clinical trials on Goiter. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Goiter Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Sanofi Johnson & Johnson IBSA Institut Biochimique SA CROss Alliance

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Precocious Puberty Global Clinical Trials Review, H2, 2015

Precocious Puberty Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Precocious Puberty clinical trials scenario. This report provides top line data relating to the clinical trials on Precocious Puberty. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Precocious Puberty Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

AstraZeneca Plc Ipsen S.A. AbbVie Inc. Abbott Laboratories Takeda Pharmaceutical Company Limited Orphan Reach Limited JLL Partners, Inc. Endo International Plc Debiopharm Group Daewoong Co., Ltd.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hypogonadotropic Hypogonadism Global Clinical Trials Review, H2, 2015

Hypogonadotropic Hypogonadism Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Hypogonadotropic Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Hypogonadotropic Hypogonadism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Hypogonadotropic Hypogonadism Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Repros Therapeutics Inc. Takeda Pharmaceutical Company Limited Merck & Co., Inc. Bayer AG Apricus Biosciences, Inc. Intertek Group plc Eli Lilly and Company Celerion, Inc. Amneal Pharmaceuticals, L.L.C. Abbott Laboratories

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Oligozoospermia Global Clinical Trials Review, H2, 2015

Oligozoospermia Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Oligozoospermia clinical trials scenario. This report provides top line data relating to the clinical trials on Oligozoospermia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Oligozoospermia Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Vedic Lifesciences Pvt. Ltd. Pantarhei Bioscience BV Leading Edge Marketing Joincare Pharmaceutical Group Industry Co., Ltd. Health Ever Bio-Tech Co., Ltd. Centre Hospitalier Universitaire de Nice

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Male Contraception Global Clinical Trials Review, H2, 2015

Male Contraception Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides top line data relating to the clinical trials on Male Contraception. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Male Contraception Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Bayer AG Merrion Pharmaceuticals Plc Merck & Co., Inc. GlaxoSmithKline Plc Acrux Limited

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Abdominal Abscess Global Clinical Trials Review, H2, 2015

Abdominal Abscess Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Abdominal Abscess clinical trials scenario. This report provides top line data relating to the clinical trials on Abdominal Abscess. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Abdominal Abscess Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Pfizer Inc. Bayer AG C. H. Boehringer Sohn AG & Co. KG Allergan Plc Otsuka Holdings Co., Ltd. Johnson & Johnson F. Hoffmann-La Roche Ltd.

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hirsutism Global Clinical Trials Review, H2, 2015

Hirsutism Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Hirsutism clinical trials scenario. This report provides top line data relating to the clinical trials on Hirsutism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Hirsutism Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Shire Plc Tricholog GmbH Stragen Holding Sandoz International GmbH DM Contact Management Cosmo Pharmaceuticals S.p.A Barij Essence Pharmaceutical Company

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hyperprolactinaemia Global Clinical Trials Review, H2, 2015

Hyperprolactinaemia Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Hyperprolactinaemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperprolactinaemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Hyperprolactinaemia Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Mylan N.V. inVentiv Health, Inc. Endo International Plc XOMA Corporation Merck KGaA Johnson & Johnson

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H2, 2015

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Neurocrine Biosciences, Inc. Fusion IP plc Novartis AG Mitsubishi Chemical Holdings Corporation Johnson & Johnson GlaxoSmithKline Plc

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Premature Ejaculation Global Clinical Trials Review, H2, 2015

Premature Ejaculation Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Premature Ejaculation clinical trials scenario. This report provides top line data relating to the clinical trials on Premature Ejaculation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Premature Ejaculation Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Plethora Solutions Holdings Plc Johnson & Johnson Ixchelsis Ltd GlaxoSmithKline Plc Ampio Pharmaceuticals, Inc. Symyoo Pfizer Inc. Emcure Pharmaceuticals Ltd. Dong-A Socio Group Ctcbio Inc.

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Peyronies Disease Global Clinical Trials Review, H2, 2015

Peyronies Disease Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Peyronies Disease Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Endo International Plc Dimensione Ricerca S.r.l. (Inactive) Allergan Plc TFS International AB Men's Health Boston Imprimis Pharmaceuticals, Inc. Hybrid Medical, LLC

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Male Sexual Dysfunction Global Clinical Trials Review, H2, 2015

Male Sexual Dysfunction Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.

This report provides an overview of Male Sexual Dysfunction clinical trials scenario. This report provides top line data relating to the clinical trials on Male Sexual Dysfunction. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Male Sexual Dysfunction Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Bayer AG Pfizer Inc. Eli Lilly and Company GlaxoSmithKline Plc Vivus, Inc. Dong-A Socio Group Johnson & Johnson SK Chemicals Co., Ltd. Plethora Solutions Holdings Plc Allergan Plc

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###